Global Health Ltd (Medanta) Q2 FY26 – ₹11,189 Mn Revenue, ₹1,584 Mn PAT, Noida Hospital Operational, Mumbai Project Swells to ₹1,530 Cr: The Doctor’s Empire Just Got Bigger (and Richer)
1. At a Glance
Global Health Ltd, the proud parent of Medanta, just checked into the ICU of corporate India with a diagnosis called “healthy profitability.” With a market cap of ₹33,660 crore and a stock that trades at a premium P/E of 56.3x, the company continues to show what happens when healthcare meets scale, systems, and scandal-free execution (a rare combo in Indian hospitals).
In Q2 FY26, Medanta clocked ₹11,189 million in revenue and a PAT of ₹1,584 million, a robust 21% YoY growth, while quietly inaugurating its shiny 550-bed Noida hospital. As if that wasn’t enough, management also dialed in a project update – Mumbai’s hospital capacity got “accidentally expanded” to 750 beds, pushing its total capex to ₹1,530 crore. Clearly, inflation isn’t just hitting grocery bills; it’s also inflating hospital budgets.
At ₹1,252/share, the stock is down 12% over three months, probably because traders didn’t get free check-ups with their holdings. But ROCE at 19.7%, ROE at 16.5%, and debt-to-equity at 0.21x tell you this doctor still runs a very clean financial chart.
And with over 3,000 operational beds, 1,750+ doctors, and 6 clinics, Medanta is no longer just a hospital chain — it’s a healthcare kingdom with ICUs the size of five-star lobbies.
2. Introduction – The Billionaire with a Stethoscope
If Indian hospitals were people, Medanta would be that classy, well-groomed doctor who charges you ₹1,000 just for saying “Hmm.”
Founded by Dr. Naresh Trehan, Global Health Ltd runs its business like an elite surgical unit — high precision, minimal noise, and lots of billing. The Medanta brand has evolved from a single Gurgaon landmark into a North and East India healthcare empire with a growing footprint — Lucknow, Patna, Indore, Ranchi, and now Noida (freshly opened in Q2 FY26).
Over the past few years, while Apollo fought margin pressures, Fortis struggled with image rehab, and Max was trying to prove it was not a mutual fund scheme, Medanta quietly worked its way to the top quartile of hospital profitability.
ARPOB (Average Revenue per Occupied Bed) at ₹63,023 and occupancy of 61.6% aren’t random metrics — they’re a masterclass in balancing quality, pricing power, and patient turnover. The company’s average length of stay (ALOS) of 3.13 days is shorter than most Indian Netflix binges.
Global Health’s unique model of “doctor-led management” — where physicians actually help run the hospitals (what a concept!) — ensures clinical credibility stays intact while the finance team runs like a clean IV drip.
So, what’s next? Bed expansions, robotic surgeries, and more cities being vaccinated with the Medanta brand. Buckle up — the scalpel has gone national.
3. Business Model – WTF Do They Even Do?
Let’s decode the Medanta prescription:
At its core, Global Health Ltd is in the business of running multi-specialty tertiary care hospitals. Translation: you go there when you want to live, but also want an air-conditioned recovery suite with Wi-Fi.
They operate five fully functional hospitals under the Medanta brand — in Gurgaon (1,440 beds), Lucknow (751 beds), Patna (442 beds), Indore (175 beds), and Ranchi (200 beds). Add to that six outpatient clinics and diagnostic centers across Delhi NCR and Bihar.
The company provides 30+ specialties, but its revenue leaders are cardiology (21%), cancer (14%), digestive sciences (12%), neuro (12%), and kidney & urology (8%).
Now here’s the beauty: Medanta’s expansion strategy doesn’t rely on hype or franchises — it builds massive owned hospitals with long-term capex visibility. Over the next five years, it plans to spend ₹2,800 crore adding 2,900 new beds. That’s roughly ₹1 crore per bed — or as Indian families call it, “our entire lifetime savings.”
What’s unique? The doctor-governed management structure. Unlike many peers where finance people call the shots, Medanta has a Medical Board chaired by top specialists. It’s a model that earns both medical trust and operational efficiency.
So yes, they heal patients — but they also heal investors’ faith in organized healthcare.
4. Financials Overview
Metric (₹ Cr)
Latest Qtr (Q2 FY26)
YoY Qtr (Q2 FY25)
Prev Qtr (Q1 FY26)
YoY %
QoQ %
Revenue
1,119
957
1,031
16.9%
8.5%
EBITDA
247
228
247
8.3%
0.0%
PAT
158
131
159
20.6%
-0.6%
EPS (₹)
5.89
4.87
5.92
20.9%
-0.5%
Annualised EPS: ₹23.6 → Implied P/E = 53x, not cheap, but hospitals rarely are.
Commentary: Revenue is growing faster than patient waiting times, while PAT margins remain a healthy ~14%. The flat QoQ EBITDA means costs are being managed despite expansion. This is corporate India’s version of “fit and fine.”
5. Valuation Discussion – Fair Value Range Only
Let’s run through the holy trinity of valuation:
a) P/E Method
EPS (TTM): ₹20.9 Industry P/E (Healthcare): ~55x → Fair Value = ₹20.9 × (50–60) = ₹1,045 – ₹1,254/share
b) EV/EBITDA Method
EV = ₹33,256 Cr EBITDA (FY25): ₹956 Cr → EV/EBITDA = 34.8x (on current) Industry average ≈ 30x If Medanta trades near fair range → EV = 30×956 = ₹28,680 Cr → Equity Value ≈ ₹29,000 Cr → FV ~ ₹1,090/share
